StockpollyBeta
Get App
Popularity #1,100
DYN · NASDAQ · Biotechnology

Dyne Therapeutics (DYN)

Develops targeted genetic medicines for neuromuscular diseases through its FORCE delivery platform.

$16.53
vs last close−0.61 (−3.53%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000100
Gross profit000000000−100
6268697210697122116114116125182
Research & development555945629382106999795101152
7925101315161717212429
General & administrative7925101315161717212429
Other expenses000000000−100
Operating income−62−68−69−72−106−97−122−116−114−116−125−182
214798756443
Interest income223798778898
Interest expense000000003345
Other non-operating income0−1−4−7−9−8−7−5−9−14−9−8
Income before tax−60−67−66−65−97−90−115−111−108−112−121−179
Net income from continuing operations−60−67−66−65−97−90−115−111−108−112−121−179
Net income−60−67−66−65−97−90−115−111−108−112−121−179
EPS, basic−$0.99−$1.09−$0.81−$0.70−$0.96−$0.88−$1.05−$0.97−$0.76−$0.76−$0.73−$1.08
EPS, diluted−$0.99−$1.09−$0.81−$0.70−$0.96−$0.88−$1.05−$0.97−$0.76−$0.76−$0.73−$1.08
Weighted average shares, basic61618193101102110114142128165165
Weighted average shares, diluted61618193101102110114142128165165
EBITDA−62−66−65−65−97−89−115−110−105−101−116−173
Depreciation & amortization000000111111
EBIT−62−67−66−65−97−90−115−111−105−102−117−174